Businesses Appeal £100M CMA Fine For Overpriced Drug

By Silvia Martelli (November 19, 2021, 2:31 PM GMT) -- Drugmaker Advanz and two other companies have appealed against a £100 million ($134 million) fine from Britain's antitrust watchdog for inflating the price of tablets for thyroid conditions by 1,110%.

Advanz Pharma Corp. and two private equity firms, Hg and Cinven, each filed their own appeal on Thursday, in which they asked the Competition Appeal Tribunal to annul, or substantially reduce, the Competition and Market Authority fines.

The companies denied charging "excessive and unfair prices" for Liothyronine tablets, which are used to treat thyroid hormone deficiency, and abusing their dominant position in the market.

The CMA fined Advanz £40.9 million in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!